The PRWIRE Press Releases https:// 2020-02-20T01:03:39Z Supercharged medical community to unite against urgent threats to global health 2020-02-20T01:03:39Z supercharged-medical-community-to-unite-against-urgent-threats-to-global-health-2 Inspired to make meaningful change on global health issues, Intensive Care Specialists, Oliver Flower and Roger Harris from Sydney’s Royal North Shore Hospital have founded Coda – a global community of medical professionals dedicated to generating, proving and sharing revolutionary health care ideas for societal change. Backed by global health organisations, hundreds of volunteers and built on the highly successful conference series SMACC (Social Media and Critical Care), which travelled the globe from 2013-2019 accumulating 50,000 members, Coda begins where SMACC left off. The first-ever Coda conference will be held in Melbourne from 28 September to 2 October, uniting the entire healthcare community unbound by critical care. Each year, Coda will identify a specific and urgent threat to global health and deliver a draft set of tangible, achievable and sustainable actions for the community to build upon prior to the major event, with final action plans presented at the Coda conference for rapid adoption. Published via academic journals and disseminated across the community, these actions will be open for industry-wide comment, engagement and discussion via social platforms. In 2020, Coda will focus on an action agenda for climate change. Asking for a call-to-arms, Roger Harris said, “There are 60 million health care workers around the world, and as an industry, we’re leaders in society – the people who the public trust with their health, wellbeing and their lives. “Imagine if this community could come together as one to make positive and actionable change on global health crisis. We as a medical community can change humanity’s global footprint. We have the power to inspire, revitalise and provide hope for the future.” Connecting this to how Coda 2020 will have an impact, Oliver Flower said, “Coda was created to accelerate progress toward better health outcomes for all. We exist to create a healthier world together, however, to make real changes – we need fast action, not just talk. We will use Coda 2020 as a launchpad to mobilise our local and global communities – it will be the benchmark for real change.” Over an intensive five days, beginning with 40 CPD workshops, more than 50 expert speakers from across the globe will connect across four central domains at Coda 2020: Coda Earth: Threats to humanity from climate change, water and food shortages, and air pollution. Coda Cure: Threats include sepsis, pandemics, trauma, communicable disease. Coda Educate: Threats include equitable access to learning, knowledge dissemination, harms of medical misinformation particularly on vaccine hesitancy and antibiotic resistance. Coda Ethics: Threats include equity within healthcare itself, artificial intelligence, end of life care, population and genetic modification. Coda 2020 will provide a hub for the medical profession to come together to accelerate change, be empowered and make a real impact on local and global health issues. You can be the first to secure your seat at Coda 2020 from 1st April (no joke) – get in quick at codachange.org #Coda2020 @codachange -ENDS- Notes to editors: Interviews are available upon request with Coda Co-Founders Roger Harris and Oliver Flower About Coda: Coda is a global community that comes together to generate, prove and share revolutionary ideas to solve urgent global health challenges. Founded by the same team that created the SMACC (Social Media and Critical Care) worldwide conference series - which ran from 2013 – 2019 visiting Australia, Chicago, Ireland, Germany - the Coda community is driven by four key values: collaboration, action, creativity and humanity. Coda 2020 is a supercharged medical conference for professionals in the health community. It is built on a desire to improve health outcomes across the world, and the opportunity to convert that desire into action. Coda 2020 will deliver: A captivating and thought-provoking healthcare program. Incredibly inspiring speakers with compelling messages. A huge variety of program formats to stimulate and engage. Unparalleled production qualities guaranteed to capture your attention. Unforgettable social events to relax, recharge and connect. A community experience that is diverse and inclusive in every way. Roger Harris Roger Harris is a senior staff specialist in the intensive care unit at the Royal North Shore Hospital and the Sydney Adventist Hospital (SAN). He is dual qualified in Emergency Medicine and Intensive Care. Roger is one of the co-founders of Coda and SMACC (Social Media and Critical care). He is passionate about education, his five children and especially his beautiful wife Georgie. Oliver Flower Oliver Flower is a staff specialist in Intensive Care Medicine at Royal North Shore Hospital, Sydney. He is an intensivist in Sydney who’s been driving SMACC (Social Media and Critical Care), and now Coda, from their beginnings. He has steered the creative side of SMACC & Coda, from the graphic design elements to the style, marketing, website and social platform strategies. He has an interest in neurocritical care and has shaped the neuro workshops. Media Contacts: For further information, images, interviews or industry commentary, please contact ZADRO: Debbie Bradley, Group Account Director | 0420 761189 | debbie@zadroagency.com.au Event Contacts: For event and registration, please contact Coda: Phone +61 2 9431 8600 Email coda@codachange.org Website codachange.org Bitglass reports over 27 million affected by healthcare data breaches last year 2020-02-18T22:46:48Z bitglass-reports-over-27-million-affected-by-healthcare-data-breaches-last-year SYDNEY – February 20 - Bitglass, the next-gen cloud security company, has released its sixth annual Healthcare Breach Report. Each year, Bitglass analyses data from the U.S. Department of Health and Human Services’ ‘Wall of Shame’, a database containing information about breaches of protected health information (PHI). In 2019, these breaches collectively affected over 27 million individuals. Bitglass’ latest report analyses the breaches of 2019, compares them to those of previous years, and reveals key trends and cybersecurity challenges facing the healthcare industry. Breaches recorded in the database are classified into the following categories: Hacking or IT incidents: Breaches related to malicious hackers and improper IT security Unauthorised access or disclosure: All unauthorised access and sharing of organisational data Loss or theft: Breaches enabled by the loss or theft of endpoint devices Other: Miscellaneous breaches and leaks related to items such as improper disposal of data According to the findings, the total number of records breached more than doubled from 2018 to 2019. This same doubling also occurred between 2017 and 2018, revealing a dramatic upward trend over the last few years. Corresponding with this, the average number of individuals affected per breach reached 71,311 in 2019, nearly twice that of 2018 (39,739). Additionally, this was the first time since 2016 that the number of breaches reached over 300--the 386 incidents in 2019 represented a 33% increase over 2018. “Last year, ‘Hacking and IT incidents’ was the top cause of breaches in healthcare, accounting for more than 60% of all data leakage,” said Anurag Kahol, CTO of Bitglass. “This is not particularly surprising given the fact that threat actors are maturing their capabilities and adapting to security measures organizations put in place, like multi-factor authentication. “Healthcare databases are heavily targeted by cybercriminals as they hold a wealth of sensitive information like medical histories, Social Security numbers, personal financial data, and more. This means that healthcare firms must employ the appropriate technologies and cybersecurity best practices to ensure all data within their IT systems is secure around the clocks.” Key findings The cost per breached record in healthcare was $429 in 2019. Last year, with 27.5 million records exposed, data breaches cost healthcare organisations $11.8 billion. Around 24 million people were affected by healthcare breaches due to hacking and IT incidents. This category was followed by unauthorised access or disclosure, which affected 2.5 million people. Lost or Stolen Devices has consistently had the biggest annual decrease over the past few years, dropping from 148 in 2014 to 42 in 2019. The total number of records breached has more than doubled each year; from 4.7M in 2017 to 11.5M in 2018, and to 27.5M in 2019. To learn more about the state of cybersecurity within the healthcare industry over the past year, download the full report here: https://pages.bitglass.com/CD-FY20Q1---2020-Healthcare-Breach-Report_LP.html?&utm_source=pr About Bitglass Bitglass, the Next-Gen Cloud Security company, is based in Silicon Valley with offices worldwide. The company's cloud security solutions deliver zero-day, agentless, data and threat protection for any app, any device, anywhere. Bitglass is backed by Tier 1 investors and was founded in 2013 by a team of industry veterans with a proven track record of innovation and execution. ANZ media contact David Frost TouchdownPR for Bitglass 02 7902 9567 MRI PRO ANNOUNCES GLOBAL RESELLER AGREEMENT WITH SIEMENS HEALTHINEERS 2020-02-18T20:40:47Z mri-pro-announces-global-reseller-agrement-with-siemens-healthineers PEPconnect (Personalized Education Plan), an online platform providing thousands of learning modules on imaging and laboratory diagnostics, now offers access to additional education content to meet the holistic needs of the healthcare professional. With flexible technology, now everyone from the institution to the individual can have access to education in a single space, including product focused, clinical, and beyond. The first subscription offering MRI PRO, with a library of 300 PIRADS scored multi parametric prostate MRI cases, is now available on PEPconnect.   MRI PRO Co-Founder & Chairman, Assoc Prof Jeremy Grummet MBBS, MS, FRACS, said: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. However, ensuring all healthcare professionals can gain the necessary experience to maximise the value of this methodology within the prostate cancer pathway, is key. We are pleased to partner with Siemens Healthineers with the aim of improving the overall patient experience and delivering the best possible health outcomes.”   MRI PRO is an e-learning platform that trains radiologists, urologists and trainee specialists through online case-based learning-by-doing, complete with full histological verification for instant feedback. The program offers quality images validated against the standard of tissue histopathology, and provides the opportunity to earn CME and CPD points. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications.  Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback, including access to the actual histo pathology report. MRI PRO is uniquely positioned to have a significant impact on the way that doctors diagnose the disease and manage the treatment of men. MRI PRO is also accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the American Medical Association (AMA), the Royal Australasian College of Surgeons, and the Royal Australian and New Zealand College of Radiologists to earn CME points. Developed in Australia for radiologists and urologists around the world, MRI PRO is the world's largest online trainer in prostate MRI. Team of the world's top experts from universities including Cambridge, Stanford, University of California San Francisco and New York University have advised on the program.  For more information, or to see the tool in action, head to www.mripro.io Coronavirus protection now available 2020-02-15T06:48:21Z coronavirus-protection-now-available-1 A spray has been developed that leaves a protective barrier against Coronavirus, Influenza, Gastro and many other infections. It is available as a hand sanitiser, surface spray and room fumigant.  Coronavirus is not only contracted when you come into contact with someone who is infected with it, you are far more likely to contract it by touching a surface that an infected person has sneezed upon or touched.  According to a National Geographic article “How coronavirus spreads on a plane”, surfaces can remain infected for months. BITRE Aviation Statistics indicate there are over 100 million people passing through Australian airports each year, so there is a very high risk of infectious viruses spreading via surface contamination.  The spray that Mission Control HQ have developed not only kills Coronavirus, Influenza and other viruses, it also bonds to the surface and continues to kill any new pathogens it is exposed to for days, weeks, even months. Disinfectants kill germs but within minutes the surface can become infected again, when someone else with unclean hands touches it. Introducing the first Hospital Grade Disinfectant and Germ Barrier. A natural and eco-friendly product made in Australia and affectionately called “Nuke”. Nuke™ bonds to surfaces, then penetrates and ‘explodes’ germs that come into contact with it. Use the spray on surfaces that get touched by many, to protect everyone that touches it. Use the atomiser on hands, for personal protection, or to clean touch screens that are shared. Because you never know how clean things are. Also available as a concentrate which can be used as strong cleaning product, a room fumigant or as refills for the spray and atomiser (dilution ratios are on the bottle). Cannabis Cultivation regulation compliance in Australia 2020-02-14T02:36:19Z cannabis-cultivation-regulation-compliance-in-australia Starting a medicinal cannabis business in Australia can be a daunting process. Investors and operators need to have access to technical and engineering expertise to produce healthy, sustainable and saleable cannabis crops, pharmaceutical products and source materials.   There are complex documentation requirements for licence applications, including site selection studies/soil tests, seed sourcing, crop planning programs, supplier audits, environmental monitoring, and mandated personnel training and security programs. Cost-effective climate controls are also necessary to avoid negative net incomes/declining profit margins.  Meeting national and international regulations, e.g., GACP, GMP requirements, can be challenging for individuals accustomed to working in less-regulated sectors. Globally, significant volumes of rejected cannabis crops and recalled medicines have had to be destroyed due to quality and safety concerns. These are some of the key factors that have impacted the industry’s profit margins and share prices.  Instability of corporate boards and/or management teams is also an issue for this industry, often initiated after a lack of profits and/or a steep decline in profit margins, over time. But like all businesses, start-up investment costs will take time to generate a return.  Despite unprecedented growth rates in demand --- in some regions, exceeding 200% to 400% a year – operational efficiencies are a necessity for sustainability. The fact is, it’s a lucrative industry, but an increasingly competitive field as more licences are granted across the world. Capital investment decisions and future expansion plans must be built into these businesses in the earliest stages of development, by experts in the sector. To reduce industry confusion about what’s required to meet stringent government and health product regulations for medicinal cannabis production and exportation, the 2nd Australian Medicinal Cannabis Conference is being held in Melbourne, over 2 days, 23 to 24 March 2020. For more information visit: ….https://www.pharmout.net/ or https://www.pharmout.net/medicinal-cannabis-conferences/australian-medicinal-cannabis-conference/ Media Release: MDMA-assisted psychotherapy for bushfire victims - Fast-tracked access needed for breakthrough PTSD treatment 2020-02-13T10:30:31Z mdma-assisted-psychotherapy-for-bushfire-victims It is estimated that 800,000 Australians suffer from post-traumatic stress disorder (PTSD). Mental health experts predict this staggering figure will rise sharply as a result of the trauma experienced by families and first responders who have had their lives or safety threatened by the catastrophic bushfires this summer.In response to this mental health crisis, Mind Medicine Australia (MMA) has called for the fast-tracking of access to MDMA-assisted psychotherapy for the treatment of PTSD. MMA is a not-for-profit organisation established to promote the development of research-backed and regulatory-approved Medicine-Assisted Therapy in Australia.Doctors typically treat people who have PTSD with psychotherapy and pharmaceutical medicines. But the medications can often produce unpleasant side effects and show a mere 20%-30% success rate for patients. Exposure therapy is more successful, providing relief from PTSD in around half of cases. However, the treatment process can be long and extremely gruelling, causing many patients to drop out.In contrast, recent clinical trials of MDMA-assisted psychotherapy in the United States have shown to relieve PTSD immediately after just three active dose sessions for 54% of participants. A 2018 study specifically in first responders and veterans showed that patients improved further at a 12-month follow up with 67% of them in remission. The results of a separate study showed than an astounding 76% of participants did not meet the clinical diagnostic criteria for PTSD a year after the conclusion of treatment.The research has been so promising that the American Food and Drug Administration (FDA) granted MDMA-assisted psychotherapy Breakthrough Therapy status in 2017. The FDA is expected to give full regulatory approval for the treatment in the next few years after the current Phase 3 trials are completed. Earlier this month, however, an Expanded Access Program was authorised by the FDA that permits the use of MDMA-assisted psychotherapy in the United States this year, ahead of the conclusion of clinical trials. Similarly, Israel, Switzerland, and Canada have recently begun Compassionate Use Schemes that enable PTSD patients to access this therapy.Peter Hunt AM, Chair of MMA, says that Australia needs to follow the lead of these countries quickly. “These medicines have been proven to be very safe when used as part of psychotherapy in a clinically controlled environment. The Australian Therapeutic Goods Act allows the use of medicines which are not listed on the Therapeutic Goods Register under the Special Access Scheme. Australia needs to act now and expedite the availability of MDMA-assisted psychotherapy through this program to relieve the suffering of bushfire victims and others with PTSD.” Tania de Jong AM, Executive Director of MMA, agrees that an urgent shift in approach is needed. “The Australian government has allocated $76 million for distress counselling and mental health support for those affected by the bushfires. Despite the best of intentions, the current treatment methods don’t help all people who have developed PTSD. The evidence shows that MDMA-assisted psychotherapy not only works but, in the long term, will also be highly cost-effective for taxpayers.” Bushfire-affected people who have developed PTSD may experience ongoing feelings of panic or extreme fear. Without effective treatment, the debilitating symptoms can last for many years or even a lifetime. It is a condition that can act as a catalyst in a person for depression, substance abuse, and suicide, and is linked to unemployment, homelessness, and family violence.Statistics show that 10% of first responders have PTSD, and a third of them endure high psychological distress. They have suicidal thoughts at twice the rate of adults in the general population, and one first responder takes his or her own life every six weeks.According to the Productivity Commission’s 2019 Mental Health Report, the total cost of mental illness and suicide to the Australian economy is $180 billion per year.MDMA used in Medicine-Assisted Therapy and within a clinically controlled environment is not the street drug Ecstasy. Substances sold illegally often have adulterants and are usually taken in risky settings with high doses. The medicine is not a cure in itself but a facilitator for the therapeutic process. It decreases activity in the amygdala, part of the brain associated with traumatic memory, and reduces fear and defensiveness while increasing empathy, trust, and safety. Only two or three active dose sessions are needed in contrast to antidepressant treatments that usually require daily medications. Due to the ease of the treatment process, patient adherence rates are much higher with MDMA-assisted psychotherapy compared to other psychotherapies, like exposure therapy. Like MDMA, mounting clinical research indicates that psilocybin, a naturally occurring compound derived from what is colloquially known as magic mushrooms, can provide highly effective solutions for various mental illnesses when used in a clinically controlled environment in conjunction with psychotherapy. Studies show that both these medicines are physiologically safe and are not addictive. Universities that have researched these medicine-assisted psychotherapies include Harvard, Oxford, Cambridge, NYU, Imperial College, Yale, and Kings College, among many others.Mind Medicine Australia is co-funding Australia’s first clinical trial of Medicine-Assisted Therapy at St Vincent’s Hospital in Melbourne. Participating palliative care patients experiencing depression and anxiety are being treated with psilocybin. Mind Medicine Australia anticipates that more clinical trials will be announced at major research institutions in Australia soon.MMA was founded by social entrepreneurs Peter Hunt AM and Tania de Jong AM following their successful experience setting up other charities and working with people diagnosed with a mental illness. Visit mindmedicineaustralia.org for comprehensive information about the organisation. For all media enquiries, including interviews and images, please contact: Brad Grimshaw, Communications Consultant E: brad@mindmedicineaustralia.org  M: 0476 230 970 Tania de Jong AM, Executive Director E: tania@mindmedicineaustralia.org  M: 0411 459 999 Mind Medicine Australia celebrates its first anniversary - A year of many achievements, exciting new developments in the pipeline, and special film events in Melbourne and Byron Bay 2020-02-12T20:05:46Z mind-medicine-australia-celebrates-its-first-anniversary Mind Medicine Australia (MMA), one of the nation’s most progressive mental health charities, celebrates its first anniversary today on Thursday, 13 February 2020. The organisation was established for the development of research-backed and regulatory-approved Medicine-Assisted Therapy—that is, psilocybin and MDMA assisted psychotherapies—in Australia. It’s been a fast-paced year for MMA, and packed with numerous achievements, several of which have paved the way for new and exciting advances for Medicine-Assisted Therapy in 2020. These include Australia’s inaugural International Summit on Psychedelic Therapies for Mental Illness coming to Melbourne this November, the country’s first Medicine-Assisted Therapist Training Program, and the planning of an Asia-Pacific Centre of Psychedelic Medicine in Australia. To mark the first-anniversary milestone, two special film events will take place on Wednesday, 19 February, at Cinema Nova in Melbourne. After its premiere screening sold out last year, Trip of Compassion, the highly acclaimed Israeli documentary that follows PTSD patients undertaking MDMA-assisted psychotherapy, returns for an encore showing at 6.30pm. The equally popular Fantastic Fungi, an eye-opening exploration of the complex and healing nature of the mushroom world, screens separately at 7.15 pm. Both films will be followed by a Q & A, with a panel featuring Peter Hunt AM and Tania de Jong AM, co-founders of MMA, along with Renee Harvey, a clinical psychologist from Imperial College London and psychiatrist Dr Nigel Strauss. Next month, Trip of Compassion will premiere in Byron Bay on Saturday, 7 March, at 8 pm at the Byron Theatre. A Q & A will follow the screening with a panel that includes Steve McDonald, a local army veteran who has been successfully treated for Post-Traumatic Stress Disorder (PTSD) with MDMA-assisted psychotherapy. For bookings, visit mindmedicineaustralia.org/events/. Peter Hunt AM, Chair of MMA, says there is much to celebrate on the organisation’s first anniversary: “10 educational events rolled out nationally to over 2000 people,  40 pieces of editorial coverage in the media, 50 appearances by our team at outreach events, and more than 80 regular financial donors secured. MMA has been enormously successful so far in raising awareness and support for Medicine-Assisted Therapy in Australia.  As we begin our second year of operations, and as our vision continues to grow, we ask the public, government, medical community and corporate leaders for further help, so that we can move several steps closer to making this treatment available to the millions of Australians suffering from mental illnesses.” Tania de Jong AM, Executive Director of MMA, agrees that significant progress has been made over the past year in fostering public approval for the availability of Medicine-Assisted Psychotherapy in Australia. “We have seen a tide-change in the curiosity about the use of these therapies for depression, anxiety, PTSD, addiction, obsessive-compulsive disorder, anorexia, dementia and other mental illnesses. In response to this mounting public interest, we have worked closely with key stakeholders to expedite several initiatives that will help to introduce Psilocybin-assisted and MDMA-assisted psychotherapies in Australia as quickly as possible, and to keep them affordable, so that their cost is not a barrier to their accessibility." MMA is a funding partner for Australia’s first Medicine-Assisted Therapy clinical trial at St Vincent’s Hospital, Melbourne. The study has seen participating palliative care patients experiencing end-of-life anxiety and depression being given psilocybin, a naturally occurring compound derived from what is colloquially known as magic mushrooms, in conjunction with psychotherapy in a clinically controlled environment. This landmark research has set an important precedent for the mental health sector in Australia, enabling more clinical trials of Medicine-Assisted Therapy to follow at major Australian institutions soon. Australia’s inaugural International Summit on Psychedelic Therapies for Mental Illness will be hosted by MMA from 19–20 November at Sofitel Melbourne on Collins, bringing together healthcare professionals, scientists, academics, philanthropists, lawmakers, policy leaders, businesspeople, investors and consumers. The two-day event will feature a wide-ranging program with a mix of international and local keynotes, workshops, hot spots, panel conversations, and a gala dinner with Q & A. The speakers’ line-up will feature 14 international researchers and thought leaders, alongside Mind Medicine Australia Ambassadors. Early bird tickets are on sale now at summit.mindmedicineaustralia.org The first-ever Medicine-Assisted Therapist Training Program in Australia will begin with a workshop in Melbourne between 16–17 November. The course will be conducted by leading practitioners from the US and UK for qualified healthcare professionals who are eager to gain a detailed understanding of this ground-breaking treatment for mental illnesses. The full training program will commence in 2021, and graduates will be well-positioned to meet the demand for Medicine-Assisted Therapy in the likelihood that it becomes available in Australia in the coming years. For more information, visit mindmedicineaustralia.org/psychedelic-therapist-training-program/ MMA is thrilled to be developing partnerships with Imperial College London and John Hopkins University in the US to develop an Asia-Pacific Centre of Psychedelic Medicine in Australia. While planning for the centre has only just begun, MMA can reveal it will be the first of its kind in this country and is envisioned to be a world-class institution for the region. More information will come later in 2020. The development of Medicine-Assisted Therapies utilising Psilocybin and MDMA in Australia follows international research that has been so successful that the American Food and Drug Administration (FDA) has granted them Breakthrough Therapy Status. The FDA has created Expanded Access Schemes to allow people in need to undertake these therapies ahead of the conclusion of clinical trials and is expected to give full regulatory approval for these treatments in the US soon. Visit mindmedicineaustralia.org for more information about our quest to introduce Medicine-Assisted Therapy to Australia.For all media enquiries, including interviews and images, please contact:Brad Grimshaw, Communications Consultant E: brad@mindmedicineaustralia.org  M: 0476 230 970Tania de Jong AM, Executive DirectorE: tania@mindmedicineaustralia.org  M: 0411 459 999 MRI PRO & BXTACCELYON ON A MISSION TO COMBAT INACCURATE DIAGNOSIS OF PROSTATE CANCER 2020-02-11T00:56:43Z mri-pro-amp-bxtaccelyon-on-a-mission-to-combat-inaccurate-diagnosis-of-prostate-cancer With high-level evidence[1] now confirming prostate MRI’s place in the diagnostic process of prostate cancer detection, as well as adoption of the methodology in NICE[2], EAU[3], AUA[4] and national and international urology and radiology guidelines, demand for healthcare professionals experienced in interpreting and accurate reporting of MRI scans is skyrocketing. Gaining the experience that is required for accurate interpretation of prostate MRI is essential, l but is difficult to obtain without the availability of immediate histological feedback. MRI PRO addresses this global, unmet need.   MRI PRO is a subscription-based e-learning platform that allows healthcare professionals to test themselves on 300 of the highest quality histology-verified prostate MRI cases. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications, including access to histology reports.  Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback on how they did, including access to the actual biopsy report. MRI PRO is uniquely positioned to have a significant impact on the way that doctors diagnose the disease and manage the treatment of men.   MRI PRO is also accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the American Medical Association (AMA), the Royal Australasian College of Surgeons, and the Royal Australian and New Zealand College of Radiologists to earn CME points.   MRI PRO Co-Founder & Chairman, Assoc Prof Jeremy Grummet MBBS, MS, FRACS, said: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. However, ensuring all healthcare professionals can gain the necessary experience to maximise the value of this methodology within the prostate cancer pathway, is key. These are values which are also closely mirrored by the team at BXTAccelyon; their approach to training whole prostate cancer teams in the PrecisionPoint biopsy device is one we welcome, and are keen to mirror. We are pleased to partner with BXTAccelyon with the aim of improving the overall patient experience and delivering the best possible health outcomes.”   Saheed Rashid, Managing Director, BXTAccelyon, adds: “Earlier and better detection of prostate cancer is proven to widen the available treatment options to patients, which will improve outcomes whilst reducing potential adverse side-effects and / or relapse. In recent years, we have made great strides in transforming traditional biopsy techniques, however, it is still the case that we currently diagnose cancers that are harmless, leading to unnecessary investigations and operations, and we miss cancers that are harmful.    “Prostate MRI represents the next stage in prostate cancer diagnosis, but there is an unmet demand for education and training in MRI imaging and interpretation by urologist and radiologist. BXTAccelyon is therefore delighted to be the global distribution partner for this online learning platform that is paving the way for MRI education.” Made in Australia for radiologists and urologists around the world, MRI PRO is the world's largest online trainer in prostate MRI. A team of the world's top experts from universities including Cambridge, Stanford, University of California San Francisco and New York University have advised on the program.  For more information, or to see the tool in action, head to www.mripro.io   About MRI PRO PTY LTD: MRI PRO is a world’s industry standard online prostate MRI training tool designed to help doctors and health care professionals required to accurately diagnose prostate cancer scans from MRI machines and to learn how best to interpret these images.  For media enquiries and/or high-resolution images please contact alext@mripro.io [1] https://prostatecanceruk.org/about-us/projects-and-policies/mpmri [2] https://www.nice.org.uk/guidance/ng131/chapter/Recommendations [3] https://uroweb.org/guideline/prostate-cancer/ [4] https://www.auanet.org/guidelines/mri-of-the-prostate-sop Malaysians Rush for Anti-Virus Sanitiser, NatShield(TM), after Pharmacies Restock on Concerns of Spread of Deadly Disease 2020-02-10T09:22:26Z malaysians-rush-for-anti-virus-sanitiser-natshield-tm-after-pharmacies-restock-on-concerns-of-spread-of-deadly-disease      KUALA LUMPUR, Feb 6, 2020 - (ACN Newswire) - Amidst growing concerns of infection by the Wuhan coronavirus, Malaysians queued up today at local pharmacies to stock up on a handheld NatShield(TM) sanitizer containing an active ingredient that has been proven to be effective in combating over 170 deadly pathogens including previously known coronaviruses. Malaysians queue up to buy NatShield(TM) Sanitizer to combat coronavirus Homegrown healthcare company Holista CollTech ("Holista") said, since 29 January 2020, it had rushed out the first 5,000 bottles of the initial order of 60,000 bottles of NatShield(TM) to local pharmaceutical chains including Big Pharmacy after stocks ran out earlier in January. The next batch of 15,000 bottles is being despatched to Malaysian pharmacies this week.The 20-ml sanitizer retails in Malaysian pharmacies for around MYR25.00. Each bottle of NatShield(TM) sanitizer contains 5% of Path-Away(R), a plant-based active ingredient approved by the U.S. Food and Drug Authority as well as Malaysia's Ministry of Health. It is also tested at several World Health Organization laboratories worldwide.Developed by Global Infections Control Consultants LLC ("GICC LLC") of South Carolina, U.S.A., Path-Away(R) attacks the cell walls of the microbes, inhibiting their uptake of amino acids needed for reproduction. The microbes then clump together and kill themselves in the process. The alcohol-free Path-Away(R) is not harmful to humans and is currently sent for testing its effectiveness against the Wuhan-originated novel coronavirus.Kuala Lumpur-based Holista, which is listed in Australia, is the exclusive Path-Away(R) distributor in the ASEAN region. It ships in the active ingredients which are then bottled under strict guidelines at several bottling plants in Malaysia. Holista distributes NatShield(TM) to three chains representing over 3,000 pharmacies across Malaysia.At a briefing at Big Pharmacy's outlet in Petaling Jaya, Dr Rajen Manicka, Holista's CEO, said: "The response has been overwhelming. After stocks ran out on 29th January 2020, we have been working around the clock to fulfill orders in Malaysia. To date, we have received confirmed orders for 42,000 bottles of which 5,000 bottles were sold by the end of last week.""To cope with the demand, we intend to raise shipments to Malaysia from the original 60,000 bottles to 145,000 bottles by the end of February and include both 20-ml and 30-ml sizes. We also plan to offer a 60-ml family-sized bottle in the coming weeks. Beyond Malaysia, we have also received many overseas enquiries and we will update on shipment increases in the next few weeks," he added.Adding on to this, Lee Meng Chuan, the CEO of Big Pharmacy, said, "We are doing our best to cope with demand across all 71 outlets. The health and well-being of our customers are the priority. We will work closely with Holista in the coming weeks to meet customer orders."Holista has agreed to participate in an initiative by the Malaysia External Trade Development Corporation ("MATRADE"), the national trade promotion agency, to support victims of the Wuhan coronavirus. This initiative is known as 'HELP WUHAN'. Holista has donated RM10,000 as an initial donation and will further donate 2% of its sales revenue of the NatShield (TM) sanitizers.Dato' Dr Rajen also announced that Holista will also accelerate the development of a nasal balm, using the Path-Away(R) active ingredient, which can reduce risk of infection. Holista intends to file by March 2020 its own global patent for the nasal balm with a view to offer a consumer product to the international consumer market by Q3 2020.The ingredients of Path-Away(R) are certified as Generally Regarded As Safe ("GRAS") and approved by the U.S. Food and Drug Administration (FDA) and exempted by the U.S. Environmental Protection Agency (EPA). It is listed in the United States Pharmacopeia (USP) and has undergone successful USP-51 testing as a disinfectant.Path-Away(R) is also approved by the Food and Safety Authority and Environmental Protection Authority of New Zealand. It is approved for use by Malaysia's Ministry of Health, with special reference to the H1N1 virus.Holista is licensed to manufacture and distribute NatShield(TM) in Southeast Asia.About Holista CollTech LtdHolista CollTech Ltd ("Holista") is a research-driven biotech company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth and with extensive operations in Malaysia, the company is dedicated to delivering first-class natural ingredients and wellness products globally. Holista is a leader in the research of herbs and ingredients for the making of healthier food.Listed on the Australian Securities Exchange ("ASX"), Holista researches, develops, manufactures and markets "health-style" products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients, among other things, includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low calories sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.comContact:Corporate Affairs & Business OpportunitiesDr Rajen Manicka: rajen.m@holistaco.comGeneral Enquiries: enquiries@holistaco.comMedia and Investor Relations:WeR1 Consultants Pte LtdE: holista@wer1.net; P: +65 67374844 Wireless Nurse Call demonstrates improved flexibility and timesaving for increased functionality and safety with CarePlus™ 2020-02-05T01:44:52Z wireless-nurse-call-demonstrates-improved-flexibility-and-timesaving-for-increased-functionality-and-safety-with-careplus CarePlus™ Wireless has developed a strong reputation as one of the best performing Nurse Call platforms available at NiQ Health since its launch only a short two years ago.  CarePlus™ Wireless facilitates versatile IP Nurse Call, operating next-generation, real-time wireless communication suitable for a range of facilities in the medical industry, from acute care to aged care, to GP clinics, and small day surgeries.  It is the freedom of choice and location, with no cabling required thereby eliminating building constraints accompanying wired Nurse Call systems, that allows a more efficient CarePlus™ Nurse Call installation.  Advantageous benefits such as easier integration, simpler connectivity and limited maintenance ensures faster performance, improving compliance whilst guaranteeing safety expectations are met. Improved functionality also offers benefits such as increased battery life (7 years), reliability and a user-friendly system to deliver staff, patients, and their families, significant peace-of-mind.   To explore why CarePlus™ Wireless is right for you, please click here. Evidentli appoints Jenny Morawska to the Board of Directors 2020-02-05T01:35:06Z evidentli-appoints-jenny-morawska-to-the-board-of-directors Sydney, Australia. Evidentli, a global leader in medical research automation and translational medicine announced today that Jenny Morawska has joined the Board of Directors. Commenting on her appointment Guy Tsafnat, Founder and Chairman of Evidentli said, “We are thrilled to attract a leader of Jenny’s calibre to our Board and we look forward to working with her in continuing to chart Evidentli’s expansion in the coming years.” Greg Miner, co-Founder and CEO stated, “Jenny possesses a rare combination of expertise in corporate governance and a deep understanding of medical research. She will bring strong oversight and counsel to our Board as we continue to transform the technical landscape surrounding medical research and translational medicine.” Jenny is an accomplished commercial businesswoman with deep experience as a Senior Executive across multiple industries and diverse stakeholder groups. Her commercial acumen and successful business career have been underpinned by her training as a research scientist and her further career as a financier and banker. Jenny was one of the four most senior women in Australian Federal Government. She is also a pragmatic commercial businesswoman who for the last 15 years has worked on the global stage. Her career includes: CEO of a Biotechnology Company; GM of an international Bank; Executive Director of Price Waterhouse and Deputy CEO of the Federal Departments of Finance and Industry, Science and Resources. She has a comprehensive understanding of global organisations, experience in working across and within cultures, leading diverse teams and developing future leaders. She is currently a Director of Research Australia where she Chairs the Strategy and Membership Committee and is a Member of the Awards Committee; a Foundation Board Director of Queensland Mind and Neuroscience – Thompson Institute; a member of the Governing Council of the University of the Sunshine Coast and Member Risk, Governance and Performance Committee; and a Director of the Lifeboat Foundation. Jenny is also a visiting fellow at the Garvan Institute of Medical Research, and recently completed a Google/NASA Fellowship in Exponential Technologies at Singularity University in Silicon Valley reinforcing her deep knowledge of business and technology and current possibilities for business models. About Evidentli Established in 2018, and based on 13 years of internationally funded research, Evidentli is a global leader in the automation of medical research and translational medicine. Evidentli’s technology is used by hospitals, research institutes, and government bodies in Australia and Europe. Evidentli’s team is comprised of experienced informaticians who are thought leaders in digital health, translational medicine, artificial intelligence in healthcare, and medical software development. The team has cumulatively authored over 1000 papers in these fields and holds leadership roles in international organisations such as the executive team of the International Collaboration for the Automation of Systematic Reviews, The Cochrane Collaboration, and Guidelines International Network. Orders for NatShield Sanitizer Spike after Outbreak of Coronavirus 2020-01-31T05:19:31Z orders-for-natshield-sanitizer-spike-after-outbreak-of-coronavirus    ASX-listed Holista CollTech (ASX:HCT, 'Holista') announced today a strong spike in demand in Malaysia for it all-natural disinfectant spray NatShield™ Sanitizer containing the powerful Path-Away® anti-microbial compound. The increased demand follows the recent outbreak of the deadly coronavirus originating in Wuhan, China. Holista confirmed that since mid-January 2020 it had sold all NatShield™ Sanitizer in its inventory. Each bottle of NatShield™ Sanitizer contains 5% of Path-Away®, which is made from natural plant-based substances that have been approved for use by the U.S. Food and Drug of Authority and tested by World Health Organization (WHO) approved laboratories in numerous countries around the world.Developed by Global Infection Control Consultants LLC (GICC LLC) based in South Carolina, USA, Path-Away® (www.path-away.com) is distributed in Malaysia by Holista as NatShield™ Sanitizer. Holista is the exclusive distributor of Path-Away® for the ASEAN region. ASEAN countries with confirmed cases of the coronavirus include Malaysia, Singapore, Thailand and Cambodia.Based on requests from seven chains representing over 3,000 pharmacies in Malaysia, Holista has ordered 60,000 bottles of NatShield™ Sanitizer to be air-freighted to Malaysia from the U.S.A. by mid-February.The novel coronavirus was first reported to WHO on 31 December 2019 and has been under investigation ever since. Countries with confirmed infections include the U.S.A., Canada, France, Australia, Japan, South Korea and Nepal.The active substance in the spray weakens the cell walls of the virus, causing the infectious organisms to clump together, in the process killing themselves, almost instantly. The potent compound is environmentally safe with very low toxicity and hence is not harmful to humans and pets even if accidentally swallowed. It is free of alcohol and other potentially toxic chemicals.It is approved for use by Malaysia's Ministry of Health, with special reference to the H1N1 virus - another coronavirus, similar to one in this outbreak which led to more than 70 deaths in 2009. It has also been approved by the Food and Safety Authority of New Zealand, and the New Zealand Environmental Protection Authority (EPA). It is approved by the United States Pharmacopeia (USP) and has undergone successful USP-51 testing as a disinfectant."This is not a drug. It acts by sanitising body parts. It had been consistently shown to be effective and safe to users and the environment in the most advanced biosafety laboratories in the world," said Dr Rajen Manicka, the CEO of Holista, headquartered in Kuala Lumpur, Malaysia and listed on the Australian Securities Exchange (ASX)."NatShield™ Sanitizer was created to treat previously known coronaviruses. It can be used as a precautionary spray in crowded areas including public transport. Three to five sprays are all that is needed to disinfect hands, toilet seats, doorknobs, countertops and trolley bars, with efficacy lasting up to two hours. We plan to sell it in all infected ASEAN countries," he said.Dr Arthur Martin, the President of GICC LLC (www.giccllc.com) said, "The Path-Away® formula has been proven in world-renowned laboratories including those working with WHO, to be able to kill over 170 deadly pathogens including previously existing forms of coronaviruses. Path-Away® is currently undergoing testing on the newly emerged coronavirus, designated as novel coronavirus 2019-nCoV.Dr Martin, a globally respected scientist and a member of the WHO's Stop Tuberculosis (T.B.) Board, had been previously nominated for the prestigious Kochon Prize for his work on T.B. "Humans of all ages can use Path-Away® with little or no risk of toxic effects. It retains its efficacy for hours even under extremes of temperature and is not corrosive and can be used even in sensitive installations," he said.Contact:Corporate Affairs & Business OpportunitiesDr Rajen Manicka: rajen.m@holistaco.comGeneral Enquiries: enquiries@holistaco.comMedia and Investor Relations:WeR1 Consultants Pte LtdKarishma AilsinghaniE: holista@wer1.net; T: +65 84792656About Holista CollTech LtdHolista CollTech Ltd ("Holista") is a research-driven biotech company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth and with extensive operations in Malaysia, the company is dedicated to delivering first-class natural ingredients and wellness products globally. Holista is a leader in the research of herbs and ingredients for the making of healthier food.Listed on the Australian Securities Exchange ("ASX"), Holista researches, develops, manufactures and markets 'health-style' products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients, among other things, includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low calories sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.com MedAdvisor releases its December 2019 Quarterly Report and 4C 2020-01-31T03:07:51Z medadvisor-releases-its-december-2019-quarterly-report-and-4c Melbourne, 31 January 2019 -- MedAdvisor Australia’s leading digital medication management company, has today released its Appendix 4C Report for the three-month period to 31 December 2019 and is pleased to provide an update of its progress during the period. The Company reported $2.3m (unaudited) in quarterly revenue, an uplift of 25.3% from Q2 FY19 ($1.8m)1, with annualised recurring revenue growing >30% on Q2 FY19. This brings the total (unaudited) operating revenue for 1H20 to $4.4m, up 22.1%1 on an underlying basis. The company reported operating cash receipts of $2.5m in Q2 FY20, up 42.2% on Q2 FY19 (Q2 FY19: $1.8m) and 10.3% on Q1 FY20 (Q2 FY20: $2.3m). Net cash used in operating activities was in line with expectations at ($2.4m) vs ($2.2m) in Q2 FY19. MedAdvisor closed the quarter with $16.3m in cash. Australia MedAdvisor has ~60% of Australia’s pharmacies who subscribe to PlusOne, the software-as-a-service (“SaaS”) offering. These pharmacies collectively serve ~12m Australian customers, and of those, MedAdvisor digitally connects its pharmacy customers to ~1.3 million patients. In early October, MedAdvisor announced new long-term contracts with both Chemist Warehouse and Sigma Pharmaceuticals. MedAdvisor now has long term contracts with 3 of the 4 largest pharmacy groups in Australia. Increasing pharmacy numbers is driving increased SaaS based revenue streams, with recurring revenues growing >30% on Q2FY19. Health programs continues to grow in line with trend for H1 (up >35% on H1FY19). US As previously announced, MedAdvisor will provide Digital Adherence Programs for two top 10 global pharmaceutical companies as Health Programs customers through its partnership with Adheris. The expected revenue from these Health Programs is expected to commence in H2, with 9-month pilot programs to run over 12 months, totalling approximately $825,000. Off the back of the recent investment led by HMS; an expert in supporting health funders including health insurers and government to improve patient health outcomes and reduce costs, HMS will work with MedAdvisor to leverage our capabilities for customers in the US and Australia. Asia The Singapore-based joint venture, ZP MedAdvisor Pte. Ltd. (“ZPM”) is on track for its rollout plans in the Philippines and Malaysia. In the Philippines, ZPM has completed the app development and it is now with MedExpress for testing prior to launch. In Malaysia, ZPM signed agreements with Klinify and Alpro Pharmacy group to distribute digital Health Programs to a potential addressable patient pool of 2 million+ patients. ZPM will support more than 900 Malaysian doctors using Klinify to offer digital Health Programs to their patients. Revenue from Malaysia is expected to commence in H2 FY20. UK The Day Lewis Pharmacy Group is one of the largest independent pharmacy chains in the UK owning over 270 pharmacies and servicing over 1 million customers. MedAdvisor is progressing with a highly automated Day Lewis branded version of the MedAdvisor consumer app and pharmacy software. It is expected to begin roll out as planned in H2 FY20. Robert Read, CEO of MedAdvisor commented: “This quarter was another record in operating cash receipts. The business is continuing to deliver milestones in our home market of Australia and in the US and UK. Pleasingly the validation of having clients now in the US, UK and Asia is exciting and will provide a platform for growth into a much larger patient population. The successful capital raising that was led and underwritten by HMS Global is a significant endorsement of the potential of MedAdvisor. The addressable patient pools, for whom MedAdvisor can potentially provide digital Health Programs has expanded significantly. The new pharma clients that have agreed to pilots demonstrate the scale of the US market.” ---ENDS--- For more information contact: Jennifer Duraisingam Corporate Communications Manager Tel: +61 3 9095 3036 jenniferd@medadvisor.com.au About MedAdvisor MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. Founded with a desire to simplify medication management, the highly automated and intuitive Australian software system connects patients to medication related tools and education materials from their community pharmacy. Available free on mobile and internet devices, the platform also incorporates a variety of valuable and convenient features including reminders, pre-ordering of medications and medicines information, which together has been shown to improve adherence to chronic medications by ~20%.  Since launching in 2013 MedAdvisor has connected over one million users through ~60% of Australian pharmacies and a network of thousands of GPs across Australia, and in 2018 was recognised in the AFR Fast 100. Incredible breakthrough in the war against Coronavirus 2020-01-30T04:59:01Z incredible-breakthrough-in-the-war-against-coronavirus Contrary to popular belief, Coronavirus is not only contracted when you come into contact with someone who is infected with it, you are far more likely to contract it by touching a surface that an infected person has sneezed upon or touched. According to a recent National Geographic article “How coronavirus spreads on a plane”, surfaces can remain infected for months. National Geographic stated “Respiratory illnesses can also be spread through the surfaces upon which the droplets land—like airplane seats and tray tables. How long those droplets last depends both on the droplet and the surface—mucus or saliva, porous or non-porous, for example. Viruses can vary dramatically in how long they last on surfaces, from hours to months.” Regular disinfectants and bleaches can only kill viruses that are already present, but the surface can immediately become infected again, when the next infected person touches the same surface. According to BITRE Aviation Statistics there are over 100 million people passing through Australian airports each year, thus there is an incredibly high risk of infectious viruses spreading via surface contamination. The company that makes this new surface spray is called Mission Control HQ and what they have developed not only kills Coronavirus, Influenza and other viruses upon contact, but also invisibly bonds to the surface and continues to kill any new contaminants it is exposed to. The owner of Mission Control HQ, Michelle Young, stated that “although we have used professional ATP testing equipment to prove that our product works, at this stage we are not allowed to make the claim that our product leaves a protective barrier for any specified length of time. This is due to restrictions placed upon us by the TGA (Therapeutic Goods Administration), because our product has only been approved as a Hospital Grade Disinfectant that does not make specific claims. In order for us to make any claim on how long the protective barrier will last, we need to pay more money than we have available. We are a very small family owned business and will need to start making some rather large sales before we can afford to pay for permission to make said claim.” Michelle went on to say, “I truly wish I could tell you how long the barrier lasts, as it is indeed very exciting, but, even without stating the protective barrier period, it seems that consumers are very concerned about Coronavirus and Influenza and thus there has been a recent surge in sales regardless.” For more information about the Mission Control HQ surface barrier, or to buy some, go to https://hqmissioncontrol.com/ and look for “Nuke Clean and Protect”. They also have an atomiser version, for applying to hands or touch screens, for personal protection. Kesem Health announces the appointment of Darin Hammers to its Board of Directors 2020-01-29T22:53:57Z darin-hammers-an-accomplished-senior-executive-with-significant-experience-in-sales-and-sales-management-in-the-medical-device-industry-and-specifically-in-urology-has-been-appointed-to-the-board-of-directors-of-kesem-health Darin Hammers, an accomplished senior executive with significant experience in sales and sales management in the medical device industry, and specifically in urology, has been appointed to the Board of Directors of Kesem Health. As the President and Chief Executive Officer of Cogentix Medical, Mr Hammers managed a $25M fund raising in 2016.  In 2018, Mr Hammers led a $239M transaction, selling Cogentix to Laborie Medical Technologies. Other executive roles that Mr Hammers has held include VP of Sales (Urology) at Bard Medical and Director of Sales at Boston Scientific (Urology).  He is currently the CEO of Dysis Medical. Kesem Health’s initial market is the US, and the company is now in the final stages of preparation for a commercial pilot of its iUFlow™ device.  “With his more than 20 years’ experience, Mr Hammers will have a direct impact on Kesem’s success in its initial market penetration, future fund raising, and setting the strategic direction of the company”, says Gil Hidas, CEO of Kesem Health.   “We welcome Mr Hammers to our growing team and I’m looking forward working with him during 2020 and beyond”. About Kesem Health Kesem Health is a digital health company improving the convenience, accuracy, and validity of data in support of the diagnosis and management of urological conditions. Kesem has developed a patented and approved (FDA, TGA, CE Mark) wireless bladder monitoring and measurement platform that enables early, efficient diagnosis and monitoring of urological conditions. Kesem Health’s iUFlow™ is a fully automated, easy to use bladder monitoring solution, implemented on a smart phone platform.